Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

22%

2 of 9 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

3(30.0%)

Phase 3

3(30.0%)

Phase 1

2(20.0%)

N/A

1(10.0%)

Phase 4

1(10.0%)

10Total

Phase 2(3)

Phase 3(3)

Phase 1(2)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT07280377Phase 1Recruiting

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Role: collaborator

NCT03468335Phase 3Completed

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

Role: collaborator

NCT03013946Phase 3Terminated

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Role: collaborator

NCT01348269Phase 3Completed

Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome

Role: collaborator

NCT01862965Phase 2Completed

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus

Role: collaborator

NCT01243489Phase 4Completed

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation

Role: collaborator

NCT02690220Not ApplicableCompleted

Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh

Role: collaborator

NCT01084889Completed

Anterior Pelvic Prolapse Reconstruction With TiLOOP® Total 6

Role: collaborator

NCT02021942Phase 2Completed

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Role: collaborator

NCT01278056Phase 1Completed

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis

Role: lead

NCT00775073Phase 2Completed

Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

Role: collaborator

All 11 trials loaded